Drug intelligence / Profile preview

RSV-604

Development stage: Phase 2
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

RSV-604 is a small molecule inhibitor of respiratory syncytial virus (RSV) replication. It targets the nucleocapsid protein and has shown submicromolar activity against both A and B subtypes of RSV. The drug is under investigation for its antiviral properties, particularly in post-stem cell transplant patients with RSV infection. It acts by inhibiting viral RNA synthesis and reducing the infectivity of released virus.

Other names: RSV604RSV-604RSV 604

Targets

RSV N (Respiratory syncytial virus nucleoprotein)

Beyond the preview

Go deeper on RSV-604.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSV-604.

Explore the full profile